Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer Beyond the Androgen Receptor

被引:13
|
作者
Loriot, Yohann [2 ]
Zoubeidi, Amina [2 ]
Gleave, Martin E. [1 ,2 ]
机构
[1] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada
关键词
Prostate cancer; Cabazitaxel; Cabozantinib; Dasatinib; Clusterin; Hsp27; OGX-011; RANDOMIZED PHASE-II; HEPATOCYTE GROWTH-FACTOR; DOCETAXEL PLUS PREDNISONE; SRC FAMILY KINASES; EVERY; WEEKS; C-MET; ANTISENSE OLIGONUCLEOTIDE; CLINICAL-TRIALS; EPOTHILONE-B; OPEN-LABEL;
D O I
10.1016/j.ucl.2012.07.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death in Western countries. Most patients with prostate cancer respond to initial androgen deprivation therapy but eventually progress to castration-resistant prostate cancer (CRPC). Although androgen receptor signaling remains the main driver in CRPC, a growing body of evidence suggests that other pathways are involved in this progression. This article reviews the preclinical data and current status of clinical trials therapeutically targeting tubulin, DNA repair, molecular chaperones such as CLU and Hsp27, tyrosine kinases, and DNA repair.
引用
收藏
页码:517 / +
页数:16
相关论文
共 50 条
  • [31] Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel
    Fernandez, Ovidio
    Afonso, Javier
    Vazquez, Sergio
    Campos, Begona
    Lazaro, Matin
    Leon, Luis
    Anton Aparicio, Luis M.
    ANTI-CANCER DRUGS, 2014, 25 (03) : 237 - 243
  • [32] Current therapeutic options in metastatic castration-resistant prostate cancer
    Ingrosso, Gianluca
    Detti, Beatrice
    Scartoni, Daniele
    Lancia, Andrea
    Giacomelli, Irene
    Baki, Muhammed
    Carta, Giulio
    Livi, Lorenzo
    Santoni, Riccardo
    SEMINARS IN ONCOLOGY, 2018, 45 (5-6) : 303 - 315
  • [33] Current role of cabozantinib in metastatic castration-resistant prostate cancer
    Fay, Andre P.
    Albiges, Laurence
    Bellmunt, Joaquim
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (02) : 151 - 156
  • [34] Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
    Graham, Laura
    Schweizer, Michael T.
    MEDICAL ONCOLOGY, 2016, 33 (05)
  • [35] Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
    Perner, Sven
    Cronauer, Marcus V.
    Schrader, Andres Jan
    Klocker, Helmut
    Culig, Zoran
    Baniahmad, Aria
    ONCOTARGET, 2015, 6 (34) : 35542 - 35555
  • [36] Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity
    Schutz, Fabio A.
    Buzaid, Antonio C.
    Sartor, Oliver
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 91 (03) : 248 - 256
  • [37] Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
    Gritsina, Galina
    Gao, Wei-Qiang
    Yu, Jindan
    ASIAN JOURNAL OF ANDROLOGY, 2019, 21 (03) : 215 - 223
  • [38] YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients
    Afonso, Ana
    Silva, Jani
    Lopes, Ana Rita
    Coelho, Sara
    Patrao, Ana Sofia
    Rosinha, Alina
    Carneiro, Filipa
    Pinto, Ana Rita
    Mauricio, Maria Joaquina
    Medeiros, Rui
    PHARMACOGENOMICS, 2020, 21 (13) : 919 - 928
  • [39] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [40] Sequential therapies in castration-resistant prostate cancer
    Buonerba, Carlo
    Di Lorenzo, Giuseppe
    FUTURE ONCOLOGY, 2014, 10 (02) : 153 - 155